Mesoblast (MESO) Beginning Cash Balance (2014 - 2026)
Mesoblast (MESO) posted Beginning Cash Balance of -$25.1 million for Q4 2022, down 141.45% sequentially from $60.4 million in Q3 2022.
Analysis
Mesoblast (MESO) Beginning Cash Balance (2014 - 2026) Analysis & Trends
Mesoblast has reported Beginning Cash Balance for 7 years, with the latest figure at -$25.1 million in Q4 2022.
- Quarterly Beginning Cash Balance changed N/A year-over-year to -$25.1 million in Q4 2022, while the trailing twelve-month figure through Mar 2023 was $35.4 million (changed N/A YoY) and the FY2022 annual result came in at $136.9 million, up 5.84% from the prior year.
- Beginning Cash Balance fell to -$25.1 million in Q4 2022 per MESO's latest filing, from $60.4 million in the prior quarter.
- Over five years, Beginning Cash Balance peaked at $136.9 million in Q3 2021 and troughed at -$25.1 million in Q4 2022.
- A 5-year average of $49.5 million and a median of $44.1 million in 2018 frame the typical range for Beginning Cash Balance.
- The sharpest annual moves came in 2021 and 2022: Beginning Cash Balance surged 523.09% in 2021, then sank 55.84% in 2022.
- Over 5 years, Beginning Cash Balance stood at $37.8 million in 2018, then jumped by 33.53% to $50.4 million in 2019, then sank by 57.95% to $21.2 million in 2020, then soared by 545.51% to $136.9 million in 2021, then sank by 118.3% to -$25.1 million in 2022.
- According to Business Quant data, Beginning Cash Balance over the past three periods registered -$25.1 million, $60.4 million, and $136.9 million for Q4 2022, Q3 2022, and Q3 2021 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 161.55 Mn |
| Dec 31, 2025 | 161.55 Mn |
| Jun 30, 2025 | 62.96 Mn |
| Dec 31, 2024 | 62.96 Mn |
| Jun 30, 2024 | 71.32 Mn |
| Dec 31, 2023 | 71.32 Mn |
| Jun 30, 2023 | 60.45 Mn |
| Mar 31, 2023 | 60.45 Mn |
| Dec 31, 2022 | 60.45 Mn |
| Jun 30, 2022 | 136.88 Mn |
| Mar 31, 2022 | 136.88 Mn |
| Dec 31, 2021 | 136.88 Mn |
| Sep 30, 2021 | 136.88 Mn |
| Jun 30, 2021 | 129.33 Mn |
| Mar 31, 2021 | 129.33 Mn |
| Dec 31, 2020 | 129.33 Mn |
| Sep 30, 2020 | 129.33 Mn |
| Jun 30, 2020 | 50.43 Mn |
| Mar 31, 2020 | 50.43 Mn |
| Dec 31, 2019 | 50.43 Mn |